Studies Currently Enrolling Patients

For information about clinical trials that may be opening soon, please contact the Clinical Research Center by phone (207) 973-7596 or e-mail cwhited@emhs.org.

Currently Enrolling Patients:
Cardiology clinical trials are conducted at EMMC Northeast Cardiology Associates.

For information, please contact Northeast Cardiology research at (207) 275-3831.
No open studies enrolling patients at this time.
TrialNet - Natural History Study of the Development of Type 1 Diabetes.

For more information, please contact the Clinical Research Center by phone (207) 973-7596 or e-mail cwhited@emhs.org.
No open studies enrolling patients at this time.
APPRENTICE: Acute Pancreatitis Patient Registry to Examine Novel Therapies in Clinical Experience.

For more information, please contact the Clinical Research Center by phone (207) 973-7596 or e-mail
cwhited@emhs.org.
 
Geriatric Psychiatry:
1) A Phase 3 Safety & Efficacy Study of ALZT-OP1 in Subjects with Early Alzheimer's Disease.

2) EARLY -
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer’s Dementia.

For more information, please contact the Clinical Research Center by phone (207) 973-7224 or email nvekima@emhs.org.

3) A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study).

4) SUVEN - A Phase 2A Multicenter, Randomized, Double-blind, Parallel Group, 26-Week, Placebo-controlled Study of 50 mg and 100 mg of SUVN-502 in Subjects with Moderate Alzheimer's Disease Currently Treated with Donepezil Hydrochloride and Memantine Hydrochloride.


For more information, please contact the Clinical Research Center by phone (207) 973-4263 or email keanderson@emhs.org.

5) HARMONY - A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-related Psychosis.

6) A 52-Week Open-label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease.

For more information, please contact the Clinical Research Center by phone (207) 973-7726 or email kchamberlain@emhs.org.


 
No open studies enrolling patients at this time.
 
No open studies enrolling patients at this time.
No open studies enrolling patients at this time.
No open studies enrolling patients at this time.
No open studies enrolling patients at this time.
1) PASSAGE:  Long-term, Prospective, Multinational, Parallel-cohort Study Monitoring Safety in Patients with MS Newly Started with Fingolimod Once Daily or Treated with Another Approved Disease-modifying Therapy.

For more information, please contact the Clinical Research Center by phone (207) 973-7726 or email kchamberlain@emhs.org.

2) Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry.

3) Mild and Rapidly Improving Stroke Study (MaRISS).


For more information, please contact the Clinical Research Center by phone (207) 973-7224 or email nvekima@emhs.org.


 
No open studies enrolling patients at this time.
Oncology research is conducted at EMMC CancerCare.

For information, please contact the Cancer Center at (207) 973-7478.
No open studies enrolling patients at this time.
No open studies enrolling patients at this time.
No open studies enrolling patients at this time.
No open studies enrolling patients at this time.
No open studies enrolling patients at this time.
Geriatric Psychiatry:
1) A Phase 3 Safety & Efficacy Study of ALZT-OP1 in Subjects with Early Alzheimer's Disease.

2) EARLY -
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer’s Dementia.

For more information, please contact the Clinical Research Center by phone (207) 973-7224 or email nvekima@emhs.org.

3) A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study).

4) SUVEN - A Phase 2A Multicenter, Randomized, Double-blind, Parallel Group, 26-Week, Placebo-controlled Study of 50 mg and 100 mg of SUVN-502 in Subjects with Moderate Alzheimer's Disease Currently Treated with Donepezil Hydrochloride and Memantine Hydrochloride.


For more information, please contact the Clinical Research Center by phone (207) 973-4263 or email keanderson@emhs.org.

5) HARMONY - A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-related Psychosis.

6) A 52-Week Open-label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease.

For more information, please contact the Clinical Research Center by phone (207) 973-7726 or email kchamberlain@emhs.org.


 
No open studies enrolling patients at this time.
1) Long-term, Prospective, Multinational, Parallel-Cohort Study Monitoring Safety in Patients with MS Newly Started on Fingolimod Once Daily or Treated with Another Approved Disease-modifying Therapy.

For more information, please contact the Clinical Research Center by phone (207) 973-4263 or email keanderson@emhs.org.


2) Disabilities of the Arm, Shoulder, and Hand (DASH) - Validity and Reliability among Patients Recovering from Stroke.

For more information, please contact the Clinical Research Center by phone (207) 973-7322 or email
sfathima@emhs.org.

 
No open studies enrolling patients at this time.
No open studies enrolling patients at this time.
No open studies enrolling patients at this time.
1) Global Registry for Endovascular Aortic Treatment (GREAT) Outcomes Evaluation.

For more information, contact the Clinical Research Center by phone (207) 973-7726 or email kchamberlain@emhs.org.


2) Post-Approval Study of Transcarotid Artery Revascularization in Patients with Significant Carotid Artery Disease (The ROADSTER 2 Study).


For more information, contact the Clinical Research Center by phone (207) 973-7224 or email nvekima@emhs.org.